TABLE 4.
Stratified analyses for the association between pain scales at enrollment and death, IRONMAN Registry 2017–2023
| mHSPC (N = 573) | CRPC (N = 306) | ||||
|---|---|---|---|---|---|
| Pain scale | Comparison | Age-only model HR (95% CI) | Fully-adjusted modela HR (95% CI) |
Age-only model HR (95% CI) |
Fully-adjusted modela HR (95% CI) |
| EORTC scale | 10-points on 0–100 scale | 1.08 (1.00–1.17) | 1.08 (0.99–1.18) | 1.15 (1.06–1.24) | 1.12 (1.03–1.22) |
| Average pain | 1 point on 1–10 scale | 1.14 (0.99–1.30) | 1.12 (0.97–1.30) | 1.31 (1.11–1.54) | 1.25 (1.06–1.47) |
| Worst pain | 1 point on 1–10 scale | 1.12 (1.02–1.24) | 1.13 (1.01–1.26) | 1.21 (1.07–1.38) | 1.18 (1.05–1.32) |
| Bone pain | Some vs. none | 1.02 (0.57–1.83) | 0.98 (0.54–1.79) | 2.54 (1.69–3.81) | 2.43 (1.56–3.79) |
| Bone pain | A lot vs. none | 2.48 (1.11–5.52) | 2.22 (0.99–4.98) | 3.19 (1.22–8.32) | 3.01 (1.00–9.06) |
| White (N = 704 total, 137 deaths) | Black (N = 175 total, 37 deaths) | ||||
| Pain scale | Comparison |
Age-only model
HR (95% CI) |
Fully-adjusted model
b
HR (95% CI) |
Age-only model
HR (95% CI) |
Fully-adjusted model
b
HR (95% CI) |
| EORTC scale | 10 points on 0–100 scale | 1.11 (1.04–1.18) | 1.10 (1.02–1.18) | 1.11 (1.04–1.19) | 1.09 (0.98–1.21) |
| Average pain | 1 point on 1–10 scale | 1.21 (1.07–1.37) | 1.20 (1.04–1.37) | 1.25 (1.11–1.40) | 1.24 (1.06–1.44) |
| Worst pain | 1 point on 1–10 scale | 1.14 (1.04–1.25) | 1.14 (1.04–1.25) | 1.26 (1.11–1.42) | 1.27 (1.05–1.53) |
| Bone pain | Some vs. none | 1.56 (1.05–2.32) | 1.53 (1.02–2.29) | 1.64 (0.59–4.50) | 2.85 (0.73–11.15) |
| Bone pain | A lot vs. none | 2.76 (1.64–4.64) | 2.56 (1.47–4.46) | 2.61 (0.88–7.80) | 3.57 (1.02–12.55) |
aCox model for pain and death adjusted for age at enrollment, first PSA level on-study, Gleason score, metastatic status at baseline, de novo metastases at baseline, and sites of metastases at baseline.
bCox model for pain and death adjusted for age at enrollment, first PSA level on-study, Gleason score, disease state at enrollment (mHSPC vs. CRPC), metastatic status at baseline, de novo metastases at baseline, and sites of metastases at baseline.